Why Travere Therapeutics (TVTX) Is Up 5.8% After Promising Phase 3 FILSPARI Data in FSGS Patients

• Travere Therapeutics recently presented new Phase 3 DUPLEX Study data at ASN Kidney Week 2025, showing that FILSPARI® (sparsentan) significantly reduced proteinuria and was linked to a lower risk of kidney failure in patients with focal segmental glomerulosclerosis (FSGS) compared to the standard treatment, irbesartan.
• An important insight from the announcement is that FILSPARI achieved higher rates of partial and complete remission with a favorable safety profile, positioning it as a potential first-mover treatment in an area with no currently approved therapies.
• We'll explore how FILSPARI's strong Phase 3 results in FSGS could strengthen Travere's investment narrative and future commercial outlook.

These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

Travere Therapeutics Investment Narrative Recap

To be a shareholder in Travere Therapeutics, the central belief hinges on FILSPARI’s potential to secure regulatory approval as the first treatment for FSGS and drive significant commercial expansion. The recent Phase 3 DUPLEX Study results may reinforce the short-term catalyst of FDA approval for FILSPARI in FSGS, but key risks remain, particularly the company’s financial reliance on FILSPARI amid uncertain regulatory timelines and increased competition.

Among recent announcements, the FDA’s update in September 2025 that no advisory committee is required for FILSPARI’s sNDA in FSGS is especially relevant. This development, combined with the DUPLEX Study results, could streamline the approval process, which is a crucial near-term catalyst for Travere as it seeks to unlock a high-need market with limited competition.

However, investors should be aware that despite strong data, evolving FDA review processes and shifting regulatory requirements could introduce approval delays or added hurdles...

Read the full narrative on Travere Therapeutics (it's free!)

Travere Therapeutics' outlook anticipates $832.7 million in revenue and $221.2 million in earnings by 2028. This scenario relies on a 35.6% annual revenue growth rate and a $390.2 million earnings increase from current earnings of -$169.0 million.

Uncover how Travere Therapeutics' forecasts yield a $38.50 fair value, a 7% upside to its current price.

Exploring Other Perspectives

Fair value estimates for Travere Therapeutics from the Simply Wall St Community span from US$19.04 to US$143.81, across nine separate analyses. While many market participants focus on regulatory catalysts, several also caution that future FDA actions could influence the company’s progress in unpredictable ways.

Explore 9 other fair value estimates on Travere Therapeutics - why the stock might be worth over 3x more than the current price!

Build Your Own Travere Therapeutics Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Travere Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Travere Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Travere Therapeutics' overall financial health at a glance.

Curious About Other Options?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Outshine the giants: these 25 early-stage AI stocks could fund your retirement.
• Find companies with promising cash flow potential yet trading below their fair value.
• Rare earth metals are the new gold rush. Find out which 37 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com